Thromboembolism and pregnancy

International Angiology

Volumn 20, Issue 2, 2001, Pages 103-109

  Ginsberg, J S ^a   Turpie, A G G ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; HEPARIN; HEPARINOID; HIRUDIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PREDNISONE; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BREAST FEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SAFETY; EDITORIAL; EPIDEMIOLOGY; FEMALE; FETUS; HEART VALVE PROSTHESIS; HUMAN; NURSING; OSTEOPOROSIS; PLACENTAL TRANSFER; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0034763298     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (52)

1. Resistance to activated protein C as a basis for venous thrombosis
2. Inherited thrombophilia: Resistance to activated protein C as a pathogenic factor of venous thromboembolism
3. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S: Study of 78 women
4. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: A cross-sectional study
5. Low risk of recurrent thromboembolism in pregnancy
6. The risk of antenatal subcutaneous heparin prophylaxis: A controlled trial
7. Recurrent venous thromboembolic disease and use of oral contraceptives
8. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?
9. Placental transport of heparin
10. Risks to the fetus of anticoagulant therapy during pregnancy
11. Heparin therapy during pregnancy: Risks to the fetus and mother
12. Maternal and fetal sequelae of anticoagulation during pregnancy
13. Chondrodysplasia punctata: Is maternal warfarin a factor?
14. Risks of anticoagulant therapy in pregnant women with artificial heart valves
15. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
16. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
17. Subcutaneous heparin therapy during pregnancy: A need for concern at the time of delivery
18. Heparin effect on bone density
19. Osteopenia in pregnancy during long-term heparin treatment: A radiological study post-partum
20. A prospective study of heparin-induced osteoporosis using bone densitometry
21. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
22. The effects of long-term heparin therapy on bone density. A prospective matched cohort study
23. The use of an indwelling teflon catheter for subcutaneous heparin administration during pregnancy
24. Anticoagulant, antithrombotic and thrombolytic drugs
25. May mothers given warfarin breast-feed their infants?
26. Is warfarin sodium contraindicated in the lactating mother?
27. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy
28. Use of low molecular weight heparin in pregnancy
29. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
30. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
31. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
32. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
33. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications for coumarin
34. Treatment of deep vein thrombosis with low molecular weight heparins. A meta-analysis
35. Low molecular weight heparins (LMWH) and unfractionated heparin (UFH) in the treatment of patients with acute venous thromboembolism. Results of a meta-analysis
36. Low-molecular-weight heparin in the treatment of venous thromboembolism: An updated meta-analysis
37. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound
38. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy
39. Low molecular weight heparin NOVO (LHN-1) does not cross the placenta during the second trimester of pregnancy
40. The effects of low molecular-weight and standard heparin on calcium loss from fetal rat calvaria
41. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
42. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
43. Risk of fatal pulmonary embolism in patients with venous thromboembolism
44. Outcome of pregnancy in women with valve prostheses
45. Anticoagulation of pregnant women with mechanical heart valves; a systemic review of the literature
46. Establishing a therapeutic range for heparin
47. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement
48. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders
49. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: A cross-sectional study
50. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
51. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
52. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone